Results 101 to 110 of about 2,203,981 (305)

Serious Hazards of Transfusion (SHOT) Annual Report 2007

open access: yes, 2023
SHOT is affiliated to the Royal College of PathologistsThe issues surrounding education and training raised in the 2006 report are emphasised by the findings for 2007.
Serious Hazards of Transfusion (SHOT)
core  

Real‐World Experience With Multimodal Treatment of Resectable Stage II–III Non‐Small Cell Lung Cancer: A Single Institutional Analysis

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Neoadjuvant therapy has recently become an integral component of multimodal treatment for resectable lung cancer. However, real‐world data on perioperative morbidity and treatment adherence remain limited. This study aimed to assess the feasibility and safety of different neoadjuvant treatment approaches applied within daily clinical routine ...
Raffaella Griffo   +14 more
wiley   +1 more source

Impact of Cell Saver technology on pro‐hemostatic factors transfusion in placenta accreta spectrum interventions: A 10‐year retrospective single‐center study

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Background While Cell Saver technology effectively reduces red blood cell transfusion in the perioperative setting, its impact on the need for pro‐hemostatic factors remains unclear. The use of Cell Saver could impact the requirements of pro‐hemostatic factors.
Ilan Levy   +7 more
wiley   +1 more source

Respectful maternity care: A multinational survey of maternity care providers by the World Association of Trainees in Obstetrics and Gynecology

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective This study evaluates maternity care providers' knowledge, practice, and perspectives on respectful maternity care (RMC). Methods A global cross‐sectional online survey on RMC was conducted by the World Association of Trainees in Obstetrics and Gynecology (WATOG).
Akaninyene Eseme Ubom   +20 more
wiley   +1 more source

Transfusion reaction in a case with the rare Bombay blood group

open access: yesAsian Journal of Transfusion Science, 2013
Bombay phenotype is extremely rare in Caucasian with an incidence of 1 in 250,000. When individuals with the Bombay phenotype need blood transfusion, they can receive only autologous blood or blood from another Bombay blood group. Transfusing blood group
Hayedeh Javadzadeh Shahshahani   +2 more
doaj   +1 more source

Use of Topical (Intra-articular) Tranexamic Acid to Minimise Blood Loss and Transfusion in Total Knee Replacement Surgery [PDF]

open access: yes, 2010
Introduction Total knee replacement (TKR) is a common orthopaedic procedure, with 20-70% of patients needing 1-3 units of blood, although allogeneic transfusion is not risk free.
ALSHRYDA, SATTAR,JABER,MOHR   +1 more
core  

Anti‐Erythrocyte Antibody Formation in Individuals With and Without Known Sensitisation Pathways Reflecting Indications for Extended Immunohaematology Screening

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
– The yearly incidence of anti‐red blood cell antibodies stratified by participant groups and temporal evolution. – Overall significance p = 3.756 × 10−29. ABSTRACT Background Blood transfusion therapies are of vital importance for many patient groups.
Milanka Milosavić   +3 more
wiley   +1 more source

Transfusion-related adverse events at the tertiary care center in North India: An institutional hemovigilance effort

open access: yesAsian Journal of Transfusion Science, 2011
Aim: This study was designed to analyze the incidence and spectrum of adverse effects of blood transfusion so as to initiate measures to minimize risks and improve overall transfusion safety in the institute. Materials and Methods: During the period from
Bhattacharya Prasun   +4 more
doaj  

A guideline for transfusion of red blood cells in surgical patients

open access: yes, 2000
Blood transfusion carries a real but unquantifiable risk of adverse outcome in surgical patients from infectious, immunological and cardiorespiratory morbid events.
National Blood Users Group
core  

Home - About - Disclaimer - Privacy